<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Laboratorios Aspen</title>
	<atom:link href="https://aspen-lab.com/en/feed/" rel="self" type="application/rss+xml" />
	<link>https://aspen-lab.com</link>
	<description>Nuestro valor es la Salud</description>
	<lastBuildDate>Tue, 26 Aug 2025 15:09:50 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.1</generator>

<image>
	<url>https://aspen-lab.com/wp-content/uploads/2026/02/cropped-ASPEN-Favicon-32x32.png</url>
	<title>Laboratorios Aspen</title>
	<link>https://aspen-lab.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Nioside&#174; Launch</title>
		<link>https://aspen-lab.com/en/nioside-launch/</link>
		
		<dc:creator><![CDATA[Aspen Lab]]></dc:creator>
		<pubDate>Fri, 15 Aug 2025 00:36:38 +0000</pubDate>
				<category><![CDATA[Launches]]></category>
		<guid isPermaLink="false">https://aspen-lab.com/?p=9337</guid>

					<description><![CDATA[We are proud to announce the incorporation of Nioside&#174; (Nintedanib) into our Pulmonology Division. This treatment is indicated for: Idiopathic pulmonary fibrosis (IPF) in adults. Other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Slowing the rate of lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). A rare and &#8230; <a href="https://aspen-lab.com/en/nioside-launch/" class="more-link">Continue reading <span class="screen-reader-text">Nioside<sup>&#174;</sup> Launch</span></a>]]></description>
		
		
		
			</item>
		<item>
		<title>Vaxtor&#174; Launch</title>
		<link>https://aspen-lab.com/en/vaxtor-launch/</link>
		
		<dc:creator><![CDATA[Aspen Lab]]></dc:creator>
		<pubDate>Thu, 14 Aug 2025 23:27:41 +0000</pubDate>
				<category><![CDATA[Launches]]></category>
		<guid isPermaLink="false">https://aspen-lab.com/?p=9319</guid>

					<description><![CDATA[At Laboratorios ASPEN, we are pleased to introduce Vaxtor&#174; (Ivacaftor), now part of our Oncology Division. Indicated for the treatment of cystic fibrosis, this new therapy broadens the options available for patients facing this rare and complex condition. Available presentation: Coated tablets of 150 mg. With Vaxtor&#174;, we renew our commitment to providing healthcare professionals &#8230; <a href="https://aspen-lab.com/en/vaxtor-launch/" class="more-link">Continue reading <span class="screen-reader-text">Vaxtor<sup>&#174;</sup> Launch</span></a>]]></description>
		
		
		
			</item>
		<item>
		<title>Uveren&#174; Launch</title>
		<link>https://aspen-lab.com/en/uveren-launch/</link>
		
		<dc:creator><![CDATA[Aspen Lab]]></dc:creator>
		<pubDate>Thu, 14 Aug 2025 22:08:41 +0000</pubDate>
				<category><![CDATA[Launches]]></category>
		<guid isPermaLink="false">https://aspen-lab.com/?p=9232</guid>

					<description><![CDATA[Laboratorios ASPEN incorporates Uveren&#174; (Macitentan) into its Pulmonology Division, offering a new therapeutic alternative for patients with complex respiratory conditions. This treatment is indicated for the long-term management of pulmonary arterial hypertension (PAH), a rare and highly complex disease, helping to improve the condition and quality of life of those who suffer from it. Available &#8230; <a href="https://aspen-lab.com/en/uveren-launch/" class="more-link">Continue reading <span class="screen-reader-text">Uveren<sup>&#174;</sup> Launch</span></a>]]></description>
		
		
		
			</item>
	</channel>
</rss>
